ESMO Lifetime Achievement Award

The Dutch Cancer Institute (NKI) has won the ESMO Lifetime Achievement Award, presented by The European Society for Medical Oncology, for its `excellent translational research into breast cancer´.

Photo: ESMO Lifetime Achievement Award

The NKI has bridged the field of molecular biological research and the clinic. In particular it has developed genetic assays for breast cancer that, according to ESMO, lead to better understanding of the disease and probably to more precise and less aggressive treatment.
The ESMO award – which includes ?50,000 for research - was presented for the second time; last year it went to the Breast International Group (BIG), a platform for clinical research into breast cancer.

Apologies instead of condolences
The wife of a patient, who had been treated in the ICU of the Medisch Spectrum Twente Hospital after receiving serious burns during a barbecue accident, received a questionnaire asking her to tell the hospital management about her experience with condolences she had received. The hospital letter arrived just as her husband arrived home. Its opening sentence read: ‘Recently your husband died in the intensive care ward….’ The hospital offered its apologies … better than condolences!

31.08.2007

More on the subject:

Related articles

Photo

Article • Virology

HIV genome integration mechanism decoded by German researchers

German researchers discover how HIV selects genome integration targets using RNA:DNA hybrids as guides, revealing new therapeutic approaches for controlling viral reservoirs.

Photo

News • Autonomous imaging systems

Virtual avatars inspire trust in ultrasound robots

An ultrasound examination performed by a robot can cause distress in some patients. Munich researchers have now developed a VR avatar system that makes the process feel more human.

Photo

News • Kinetic analysis of therapeutics

How boron may point the way to better therapies for head and neck cancer

A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers.

Related products

Subscribe to Newsletter